CJC/IPA Protocol
Also known as: CJC-1295/Ipamorelin, CJC/Ipa
GHRH/GHRP Combination | Growth Hormone Optimization
Overview
A dual-pathway protocol combining CJC-1295 and Ipamorelin that targets growth hormone secretion through complementary mechanisms. CJC-1295 demonstrates 2-10 fold GH increases with 6-8 day duration, while Ipamorelin provides selective GH release without cortisol elevation.
Key benefits
- Sustained GH elevation (6-8 days from CJC-1295)
- Selective pulsatile release without cortisol suppression
- Complementary dual-pathway optimization
- Preservation of natural GH rhythm
- Enhanced muscle protein synthesis and recovery
Mechanism of action
CJC-1295 activates GHRH receptors via albumin-binding DAC technology for sustained elevation. Ipamorelin selectively activates ghrelin receptors (GHSR1a) without affecting ACTH/cortisol, preserving natural pulsatile GH patterns.
Molecular data
- Type
- Peptide combination (GHRH analog + GHS)
Sequence
N/A
Indications
What the research community uses this compound for, with self-reported effectiveness.
Muscle Growth
Metabolic Health
Anti-Aging
Recovery
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 200mcg each (0.2mL if 1mg/mL) | Once daily | — |
| — | 250mcg each (0.25mL if 1mg/mL) | Once daily | — |
| — | 300mcg each (0.3mL if 1mg/mL) | Once daily | — |
| — | 150mcg each (0.15mL if 1mg/mL) | 5 days per week | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Water retention and joint swelling
- Carpal tunnel syndrome (numbness/tingling)
- Mild blood glucose elevation
- Injection site irritation with improper rotation
Contraindications
- Cancer history or active malignancy
- Severe diabetes requiring tight glucose control
- Carpal tunnel syndrome or nerve compression disorders
Monitoring
- Regular bloodwork to monitor IGF-1 levels
- Blood glucose monitoring if diabetic
- Injection site assessment for lipodystrophy
- Overall health markers and tolerability
References
Primary literature and clinical-trial data informing this entry.